Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

NCT05359081 is registered in ClinicalTrials.gov with Sumitomo Pharma Co., Ltd. as lead sponsor.

NCT NCT05359081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Lead sponsor
Sumitomo Pharma Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
May 16, 2022
Completion date
March 28, 2024
Enrollment
68 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia